Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05188729 · ClinicalTrials.gov registry record · Phase 2
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
A Phase 2 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT05188729 is a Phase 2 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 92 participants.
The verdict
NCT05188729, a Phase 2 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC). The study is expected to enroll approximately 86 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
Interventions
- DRUG Part 1: VP-315 3 Day Dosing/Week
- DRUG Part 2: VP-315 3 Day Dosing/Week - Loading Dose
- DRUG Part 2: VP-315 3 Day Dosing/Week - No Loading Dose
- DRUG Part 2: VP-315 2 Day Dosing/Week - Split Dose
- DRUG Part 2: VP-315 3 Day Dosing/Week - Split Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05188729
The ClinicalTrials.gov registry entry for NCT05188729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Part 1: VP-315 3 Day Dosing/Week is the first listed.
NCT05188729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05188729 about?
NCT05188729 is a clinical study titled "Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma". This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell ca...
What is the current status of trial NCT05188729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2022-02-01. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05188729?
The interventions under investigation include: Part 1: VP-315 3 Day Dosing/Week (DRUG), Part 2: VP-315 3 Day Dosing/Week - Loading Dose (DRUG), Part 2: VP-315 3 Day Dosing/Week - No Loading Dose (DRUG), Part 2: VP-315 2 Day Dosing/Week - Split Dose (DRUG), Part 2: VP-315 3 Day Dosing/Week - Split Dose (DRUG).
Who is sponsoring clinical trial NCT05188729?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.